Meda: FDA Approval For Onsolis Anticipated During Summer 2009
Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain).
More: continued here
Filed under: Pain / Anesthetics on June 25th, 2009
You must be logged in to post a comment.